|
Kang BH.
BMB Rep. 2012 Jan;45(1):1-6. (IF=2.167)
Kang BH, Xia F, Pop R, Dohi T, Socolovsky M, Altieri DC.
J Biol Chem. 2011 May 13;286(19):16758-67. (IF=5.328)
Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH, Tavecchio M, Goel HL, Hsieh CC, Garlick DS, Raskett CM, Lian JB, Stein GS, Languino LR, Altieri DC. Br J Cancer. 2011 Feb 15;104(4):629-34 (IF=4.831) Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer.
Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB, Stein GS, Languino LR, Altieri DC. Clin Cancer Res. 2010 Oct 1; 16(19):4779-88. (IF=7.338) (selected as a cover article) Kang BH, Altieri DC.
Oncogene. 2009 Oct 22;28(42):3681-8. (IF=7.414)
Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. Kang BH, Plescia J, Song HY, Meli M, Colombo G, Beebe K, Scroggins B, Neckers L, Altieri DC.
Ghosh JC, Dohi T, Kang BH, Altieri DC.
J Biol Chem. 2008 Feb 22;283(8):5188-94. (IF=5.328)
Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network.
Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC.
Kang BH, Altieri DC.
J Biol Chem. 2006 Aug 25;281(34):24721-7. (IF=5.328) |

